ANI Pharmaceuticals, Inc. (ANIP) Hits Milestone with Cortrophin Gel Prefilled Syringe Launch

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. ANI Pharmaceuticals, Inc. is one of them.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP), a specialty pharmaceutical company focused on rare diseases and complex generics, is accelerating its growth through new product approvals and strategic portfolio expansion in 2025. With key assets such as Purified Cortrophin Gel and retina therapies ILUVIEN and YUTIQ, the company is advancing treatments that address critical unmet needs while strengthening its generics platform.

A major milestone this year was the FDA approval of a prefilled syringe presentation of Cortrophin Gel in March 2025. Launched in the second quarter, the new format has seen strong uptake across neurology, rheumatology, nephrology, ophthalmology, and emerging uses like pulmonology and acute gouty arthritis, driving record levels of new patient starts. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) also presented preclinical data at EULAR 2025, highlighting Cortrophin Gel’s potential in collagen-induced inflammatory arthritis, and initiated a Phase 4 trial to study its use in acute gout flares. These efforts underscore the company’s strategy of broadening indications and reinforcing its leadership in rare disease care.

In addition to rare disease therapies, ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is advancing its retina portfolio with ILUVIEN and YUTIQ, backed by new clinical findings such as the NEW DAY trial for diabetic macular edema. The business is managing a U.S. promotional transition for these assets, aiming to expand indications and influence treatment approaches in ophthalmology.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.